SA
IBRX

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Immunitybio Inc (IBRX)

Operating Income

-$274.16M

TTM · Period ending: · USD

IBRX logo

IBRX Operating Income

Latest reported-$274.16M
IBRX Operating Income (-$2.27M → -$274.16M)
Powered by
High-resolution chart · PNG

What is operating income?

Operating income is profit from the core business after operating costs, before interest and income taxes.

Compare operating income

IBRX operating income history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Immunitybio Inc Operating Income — Annual fiscal periods (USD)
Period endingOperating Income (USD)Change
-256,027,000—
-344,182,000—
-362,250,000—
-351,298,000—
-330,280,000—
-220,880,000—
-66,907,000—
-98,389,000—
-99,120,000—
-124,500,000—
-238,876,000—
-6,212,000—
-2,269,000—

Frequently asked questions: IBRX operating income

What is Immunitybio Inc (IBRX)'s current operating income?

Immunitybio Inc (IBRX)'s latest reported operating income (TTM) is -$274.16M as of Sep 30, 2026. Operating income is profit from the core business after operating costs, before interest and income taxes.

How much historical operating income data is available for IBRX?

Stock Alarm Pro provides 13 dated annual fiscal periods observations for Immunitybio Inc (IBRX)'s operating income, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare IBRX's operating income to peers or set an alert?

You can compare IBRX's operating income directly against sector peers (GH, BBIO, GKOS, BTSG) on Stock Alarm Pro, open the multi-ticker series in Chart Studio, or set real-time price and valuation alerts on IBRX delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.